THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

To build that understanding, as part one of the Your Cancer Is Our Challenge program, GSK sponsored a survey of more than 800 adults with gynecological cancers—including endometrial, ovarian ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market Blenrep reduced risk of death in trial, said British drugmaker GSK predicts annual sales of over £3 billion if approved ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

During a press conference earlier today, GSK officials, alongside Governor Josh Shapiro and Department of Community and Economic Development (DCED) Secretary Rick Siger, announced the investment ...

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month ...